Sponsors
The bill increases U.S. supply-chain resilience for medical and defense needs and supports domestic industry, but it may raise costs, expand federal spending, and create oversight and fairness risks for taxpayers and small firms.
Hospitals and patients will face fewer shortages because a coordinated federal strategy will secure and diversify supplies of drugs, devices, and biologics during emergencies.
U.S. manufacturers and workers can receive targeted analysis, incentives, and payments to harden supply chains and prioritize domestic producers, likely supporting jobs and boosting the domestic industrial base.
Federal payments to harden supply chains will reduce the risk of shortages for critical defense components, improving production reliability and military readiness.
Consumers and small businesses may pay higher prices because diversification, reshoring, or government-backed production can raise production costs and supply prices.
Broad regulatory definitions, presidential waiver authority, limited (30-day) congressional certification, and added reporting requirements create oversight gaps and administrative burden that raise the risk of misuse or inefficient program administration.
Taxpayers may face higher federal spending and a larger deficit because the program expands payments and government outlays to shore up supply chains.
Based on analysis of 3 sections of legislative text.
Requires a presidential DPA-based strategy and annual reports to secure medical supply chains and authorizes payments to U.S. entities to strengthen supply-chain security.
Introduced March 3, 2026 by Maria Elvira Salazar · Last progress March 3, 2026
Requires the President to create and deliver a national strategy and yearly progress reports that use Defense Production Act (DPA) and related authorities to secure U.S. supply chains for drugs, devices, and biological products. It also adds authority for the President to make payments to U.S. entities to strengthen supply-chain security for national defense, with definitions and a short regulatory timeline for implementing the payment program. The bill sets deadlines: an initial strategy within 180 days, annual unclassified progress reports (with optional classified annexes) through September 30, 2029, a 30-day Congressional notice before any payments, and agency rules defining “supply chain” and “supply chain activities” within 90 days of enactment.